Citigroup Inc. increased its stake in Harrow Health, Inc. (NASDAQ:HROW – Get Rating) by 439.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 61,468 shares of the company’s stock after purchasing an additional 50,073 shares during the period. Citigroup Inc. owned approximately 0.23% of Harrow Health worth $907,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Marshall Wace LLP lifted its stake in Harrow Health by 4.0% in the 3rd quarter. Marshall Wace LLP now owns 26,999 shares of the company’s stock valued at $326,000 after acquiring an additional 1,030 shares in the last quarter. Barclays PLC boosted its stake in shares of Harrow Health by 44.3% in the 3rd quarter. Barclays PLC now owns 3,560 shares of the company’s stock valued at $43,000 after purchasing an additional 1,093 shares in the last quarter. Westside Investment Management Inc. increased its holdings in Harrow Health by 0.6% in the 3rd quarter. Westside Investment Management Inc. now owns 198,764 shares of the company’s stock worth $2,399,000 after purchasing an additional 1,100 shares in the last quarter. UBS Group AG increased its stake in shares of Harrow Health by 11.2% in the fourth quarter. UBS Group AG now owns 12,718 shares of the company’s stock valued at $188,000 after buying an additional 1,279 shares during the period. Finally, Boston Partners lifted its stake in shares of Harrow Health by 2.0% in the 3rd quarter. Boston Partners now owns 112,040 shares of the company’s stock valued at $1,352,000 after purchasing an additional 2,240 shares during the period. Institutional investors own 56.47% of the company’s stock.
Harrow Health Stock Down 1.6 %
HROW stock opened at $18.86 on Thursday. The firm has a 50 day moving average of $22.86 and a 200-day moving average of $17.67. Harrow Health, Inc. has a 12 month low of $6.00 and a 12 month high of $28.25. The company has a debt-to-equity ratio of 7.84, a quick ratio of 2.41 and a current ratio of 2.92.
Harrow Health (NASDAQ:HROW – Get Rating) last released its quarterly earnings results on Thursday, March 23rd. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.22. The firm had revenue of $20.33 million for the quarter, compared to analysts’ expectations of $23.26 million. Harrow Health had a negative return on equity of 1.57% and a negative net margin of 19.76%. Equities analysts expect that Harrow Health, Inc. will post 0.06 EPS for the current fiscal year.
Analysts Set New Price Targets
HROW has been the subject of several research reports. TheStreet raised shares of Harrow Health from a “d” rating to a “c” rating in a research report on Tuesday, April 11th. Lake Street Capital raised their target price on Harrow Health from $24.00 to $37.00 and gave the company a “buy” rating in a report on Monday, April 17th. LADENBURG THALM/SH SH boosted their target price on Harrow Health from $27.20 to $32.40 in a research note on Friday, May 12th. Finally, B. Riley reissued a “buy” rating on shares of Harrow Health in a research report on Thursday, May 4th.
Harrow Health Company Profile
Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harrow Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Harrow Health wasn’t on the list.
While Harrow Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
